After Doctors Deemed Her Treatment 'Non-Urgent,' 29-Year-Old Woman Receives Unexpected, Life-Threatening Diagnosis
Sarah Graham had only just turned 29 when she was diagnosed with stage 3 bowel cancer, a disease that is becoming more prevalent among younger patients
"The first thing I said to [my surgeon] was, 'Am I going to die?' to which he said, 'Look, I hope not,' " Graham recalled about learning of her diagnosis
After undergoing chemotherapy and having part of her colon removed, Graham is currently cancer-free, but she remains in a five-year period of surveillanceThe first question that Sarah Graham recalled asking her doctor after being diagnosed with stage 3 bowel cancer days following her 29th birthday was, "Am I going to die?"
Her diagnosis came in 2024 after she went to the doctor to discuss a variety of symptoms, including an approximately 44-lb weight gain, extreme pain when going to the bathroom, and blood in her stool. That July, her general practitioner sent her for a stool test, which came back inconclusive, she told Australian news outlet Mamamia.
A colonoscopy was recommended, but Graham learned that it had been deemed "non-urgent," meaning that she was unable to schedule it until November.
The Australian interior designer's symptoms continued, and she told the outlet that she decided to get a second opinion. This led to her receiving a diagnosis that is becoming more prevalent among people her age.
"I explained my symptoms again to her, and said, 'Look, [the blood] is happening almost every time I go to the bathroom now. I'm getting really scared to go to the bathroom,' " she recalled.
Graham, who became lactose intolerant at 22 and was diagnosed and treated for endometriosis at 26, said that doctors initially thought that she had "something like Crohn's or Irritable Bowel Syndrome (IBS)."
She said that they told her she was "way too young for bowel cancer."
However, after undergoing a "traumatic" colonoscopy, Graham said that nurses seemed to be giving her a wide berth in the recovery room.
"It was getting to 6 p.m. ... and I was the only one in the recovery room," she said, adding, "And, for some reason, none of the nurses were stopping to talk to me. They were all staring at a distance."
Her mom was brought back, and the surgeon finally told her that they had found a mass.
Graham was told that she needed "to move quickly" to receive treatment and was scheduled for an "urgent CT scan," with the doctor saying that the mass was "likely malignant."
After undergoing additional testing, she was diagnosed with stage 3 bowel cancer."I knew something was wrong [but] I never expected this. I felt let down, I think," she admitted. "I know my body, and I knew what I was living with and no one would listen."
Referring to the original doctor, who believed she might be suffering from hemorrhoids or a fissure, Graham wondered "what would've happened" had she waited until November to undergo her colonoscopy.
Graham had part of her colon removed and went through six months of chemotherapy.
After treatment, she said that she is undergoing surveillance for five years. However, her outlook is "good" at the moment.
"They've put me in a low risk of recurrence category but, of course, there is no life free of the burden of cancer, unfortunately," she explained.
Now, the designer is sharing a lesson that she hopes others will learn from.
"The best piece of advice I was given is that if your doctor says no to something you request, ask them to write that down. You will quickly realize that if they don't want to put their name to denying you something, and something happens later, they don't want to be liable for it," she said, adding, "If anything is out of the ordinary, you need to get it checked."
In 2025, the American Cancer Society noted that people under the age of 50 are increasingly being diagnosed with colorectal cancer. The diagnosis is also slightly more deadly than it was in the past.
The reason for the diagnosis becoming more prevalent is unclear. However, a study published in April 2025 suggested that there might be a link between children under 10 being exposed to a bacteria in some strains of E. coli. Another 2022 study links colorectal cancer and the rise in ultra-processed foods; however, this is generally in men.
Read the original article on People

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Doctor mistakenly implants wrong embryo in IVF patient mix-up
One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's. Monash IVF said the incident occurred on June 5 at a clinic in Melbourne but did not provide further details, such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It marks the second fertility clinic mix-up of its kind in the country, heightening concerns about an industry that did not have much active government oversight until recently. The clinic said the patient's embryo was mistakenly implanted under a treatment plan which called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF, which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. "This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector," said Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 25 per cent by mid-session on Tuesday, against a rising broader market. The stock is just over half its value before the April announcement. "We had thought the Brisbane clinic embryo transfer error was an isolated incident," Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. "We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations." Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said on Tuesday it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. It said it had reported the Melbourne incident to the Victorian Department of Health and industry licensing body, the Reproductive Technology Accreditation Committee (RTAC), part of industry group the Fertility Society of Australia. Victorian health minister Mary-Anne Thomas said the department was investigating the company and the incident. "Families should have confidence that the treatment they are receiving is done to the highest standard," she said. "It is clear Monash IVF has failed to deliver that, which is completely unacceptable." Fertility Society president Petra Wale said the incident would have had an emotional toll on the family, but stressed mistakes in the sector were rare. The society reiterated a call to implement nationally consistent laws around IVF. Currently, the country's IVF industry is regulated by a combination of industry bodies and state and territory health departments, resulting in a governance and compliance system that some groups say is too complex. Reports of transferring the wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind.
Yahoo
12 hours ago
- Yahoo
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBS NeurAxis's PENFS technology is the only FDA-cleared or approved treatment that is recommended in the guidelines for pediatrics, enabling momentum for large-scale insurance coverage for IB-Stim® CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ('NeurAxis,' or the 'Company') (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This inclusion represents a major catalyst for NeurAxis, unlocking the potential for large-scale insurance coverage for its flagship product, IB-Stim, and setting the stage for accelerated growth through evidence-based recommendations. 'We are thrilled that IB-Stim is now recognized as part of the standard of care for FAP in IBS,' said Brian Carrico, CEO of NeurAxis. 'This milestone offers new hope to patients and reinforces the strength of our short and long-term growth strategy. Alongside our recent FDA expanded clearances for IB-Stim and our transformative, soon-to-be-effective on January 1st, Category I CPT code, we are now well-positioned to drive substantial top-line growth and operational leverage.' He added, 'With the recent strengthening of our balance sheet and the expected rollout of more widespread insurance coverage, we are poised to accelerate our treatment option to the over 600,000 kids in the United States suffering from FAP. We estimate the addressable market for our product just in the US to be over 3 billion dollars. With these important achievements now completed, I expect that this achievement will lead to a significant expansion of insurance coverage and revenue generation.' Dr. Adrian Miranda, practicing pediatric gastroenterologist and Chief Medical Officer of NeurAxis, commented: 'Overall, consensus was reached by the committee on 25 therapies and PENFS with IB-Stim was 1 of 4 therapies that had the highest level of evidence and thus placed amongst the top in the treatment algorithm for FAP in IBS.' Dr. Miranda also added, 'IB-Stim is not available in Europe, so the treatment algorithm was formulated to establish a framework for 'shared decision making' amongst the clinician and family, as opposed to a strict top to bottom approach. This gives clinicians the option to use IB-Stim as a first-line therapy and speaks to the overall certainty of the efficacy and safety supporting our technology. We couldn't be more pleased with this result.' Developing practice guidelines for FAP in IBS in children of 4–18 years was a collaborative effort of the European and North American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN). The guidelines followed the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) approach, which is supported by the World Health Organization (WHO). The highest GRADE therapies suggested in the guidelines include PENFS, hypnotherapy, lactobacillus rhamnosus (probiotic), and soluble fiber. This rigorous, evidence-based approach that incorporates PENFS as an important treatment option for children elevates NeurAxis's profile within the healthcare industry and supports wider market adoption of IB-Stim. Abdominal pain in IBS affects millions globally, creating a multi-billion-dollar market opportunity with limited effective treatment options. IB-Stim is the only pediatric treatment option that the FDA has cleared for FAP in IBS and abdominal pain in functional dyspepsia (to include nausea symptoms) for patients 8-21 years old. IB-Stim delivers gentle electrical impulses to cranial nerve bundles in the ear, offering a safe, non-invasive alternative to drug therapies often used off-label and many of which are not suggested in the practice guidelines from NASPGHAN / ESPGHAN. For more information about NeurAxis, please visit About NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company's stock, public health issues or other events, the Company's compliance with applicable laws, the results of the Company's clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis's public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. For more information, please visit For contraindications, precautions, warnings, and IFU, please see: Contacts: CompanyNeurAxis, Investor Relations Lytham PartnersBen Shamsian646-829-9701shamsian@

Yahoo
21 hours ago
- Yahoo
A second Australian IVF mix-up shakes clinic and industry
By Byron Kaye and Kumar Tanishk (Reuters) -One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's in a second fertility clinic mix-up, heightening concerns about an industry that did not have much active government oversight until recently. Monash IVF said the error took place on June 5 at a clinic in Melbourne but did not provide further details such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It said the patient's embryo was mistakenly implanted under a treatment plan which called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo to a patient in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. "This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector," Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 24% by midsession on Tuesday, against a rising broader market. The stock is just over half its value before the April announcement. "We had thought the Brisbane clinic embryo transfer error was an isolated incident," Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. "We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations." Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said on Tuesday it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. "Whilst industry-leading electronic witness systems ... are being rolled out across Monash IVF, there remains instances and circumstances whereby manual witnessing is required," the company said. It said it had reported the Melbourne incident to state regulator the Victorian Department of Health and industry licencing body the Reproductive Technology Accreditation Committee (RTAC), part of industry group the Fertility Society of Australia. The health department and RTAC were not immediately available for comment. Reports of transferring a wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind. ($1 = 1.5330 Australian dollars)